---------------------------------------------------------------------------
MANAGEMENT'S DISCUSSION AND ANALYSIS OF RESULTS OF OPERATIONS AND FINANCIAL
CONDITION
---------------------------------------------------------------------------
OVERVIEW
Record sales of $21.62 billion reinforced the Company's position as the largest
and most comprehensive health care company in the world. Worldwide sales
increased for the sixty-fourth consecutive year, growing $2.78 billion or 14.7%
over 1995, primarily due to volume, with a total price increase of only .1%. The
Company's volume sales growth was fueled by the solid performance of products
introduced in the past few years and the continued expansion of base businesses.
Growth through new products is being driven by the Company's commitment
to investing in research and development. During 1996, $1.91 billion was
invested in research and development, the highest level in the Company's
history, emphasizing its commitment to achieving significant advances in health
care through the discovery and development of innovative, cost effective
products that prolong and enhance the quality of life. In addition to the
research and development effort, strategic acquisitions have also enabled the
Company to achieve gains in sales. The current year sales growth also includes
the full-year impact of the merger of Cordis Corporation in early 1996.
During 1996, the Company continued initiatives to streamline its
businesses worldwide and to make the organization more cost effective. The
Company views the reengineering effort as a continuous process, and one that is
essential to compete effectively while constraining price increases and
providing resources for investing in advertising, marketing, and research and
development. These initiatives, implemented during the last few years, have
increased productivity and are showing positive results.
For 1996, the gross profit margin improved from 66.9% to 67.5%, while
selling, marketing and administrative expenses as a percent of sales decreased
from 39.6% to 38.8%. Over the past two years, the improvement in gross margins
and reduced operating expenses has resulted in cost savings of nearly $600
million on an annual basis.
The continued growth in sales and increased profitability during 1996
resulted in a 16.7% increase in earnings per share to $2.17. Earnings in 1996
generated $3.89 billion in cash from operations. When combined with $3.38
billion of cash generated from operations in 1995, the $7.27 billion in cash
from operations financed capital investments and acquisitions during the past
two years, and reduced net debt (debt net of cash and current marketable
securities) by 93.9% since 1994 to $146 million.
In the U.S. and in countries around the world, health care systems
continue to be transformed. The Company believes that it is well positioned to
take advantage of these changes due to its diversification in health care,
global reach, development of cost effective unique new products, decentralized
management, dedicated employees and strong Credo values.
SALES AND EARNINGS
In 1996, worldwide sales increased 14.7% to $21.62 billion compared to increases
of 19.8% and 11.3% in 1995 and 1994, respectively. Excluding the impact of the
relatively stronger dollar in 1996, and the relatively weaker dollar in 1995 and
1994, as compared to international currencies, worldwide sales increased 16.5%,
16.7% and 10.7% in 1996, 1995 and 1994, respectively.
SALES TO CUSTOMERS
--------------------------------------------------------------------------------
Millions of Dollars
--------------------------------------------------------------------------------
Worldwide net earnings for 1996 were $2.89 billion, reflecting a 20.1%
increase over 1995. Worldwide net earnings per share for 1996 equaled $2.17 per
share, compared with $1.86 per share for 1995, adjusted to reflect the 1996
two-for-one stock split, an increase of 16.7%. The income margin for 1996 was
13.4%, the highest in the Company's history, despite an increase in the
effective tax rate of nearly a full percentage point.
Worldwide net earnings for 1995 were $2.4 billion, or $1.86 per share on a
split-adjusted basis, representing increases over 1994 of 19.8% and 19.2%,
respectively. In 1994, worldwide net earnings of $2.01 billion, or $1.56 per
share on a split-adjusted basis, increased over 1993 by 12.3% and 13.9%,
respectively.
Average shares of common stock outstanding in 1996 were 1.33 billion
compared with 1.29 billion in both 1995 and 1994 on a split-adjusted basis.
NET EARNINGS
--------------------------------------------------------------------------------
Millions of Dollars
--------------------------------------------------------------------------------
Sales by domestic companies were $10.9, $9.19 and $7.81 billion in 1996,
1995 and 1994, representing increases of 18.6%, 17.6% and 8.5%, respectively.
The increase in domestic sales in 1996 was driven by the strong performance of
products introduced in the past few years and the continued expansion of base
businesses.
Sales by international companies were $10.72, $9.65 and $7.92 billion in
1996, 1995 and 1994, representing increases of 11.1%, 21.8% and 14.2%,
respectively. All geographic areas
23
throughout the world posted strong gains during 1996. Sales in Europe increased
10.4%, while revenues in the Asia-Pacific, Africa region and the Western
Hemisphere (excluding the U.S.) increased 13.1% and 10.6%, respectively.
Excluding the impact of the relatively stronger dollar in 1996, and the
relatively weaker dollar in 1995 and 1994, compared to international currencies,
international company sales increased 14.6%, 15.6% and 13% in 1996, 1995 and
1994, respectively.
The Company achieved an annual compound growth rate of 11.9% for worldwide
sales for the ten-year period since 1986 with domestic and international sales
growing at rates of 10.6% and 13.5%, respectively. For the same ten-year period,
excluding non-recurring charges in 1986, worldwide net earnings achieved an
annual growth rate of 15.1%, while earnings per share grew at a rate of 15.8%.
For the last five years, annual compound growth rates for sales, net earnings
and earnings per share were 11.7%, 14.6% and 14.6%, respectively.
COMMON STOCK MARKET PRICES
The Company's common stock is listed on the New York Stock Exchange under the
symbol JNJ. The approximate number of shareowners of record at year-end 1996
was 138,500. The composite market price ranges for Johnson & Johnson common
stock during 1996 and 1995, adjusted to reflect the 1996 two-for-one stock
split, were:
CASH DIVIDENDS PAID
The Company increased its dividend in 1996 for the thirty-fourth consecutive
year. Cash dividends paid were $.735 per share in 1996 compared with a
split-adjusted dividend of $.64 per share in 1995 and $.565 in 1994, an increase
of 14.8% and 13.3% over 1995 and 1994, respectively. The dividends were
distributed as follows:
On January 2, 1997, the Board of Directors declared a regular cash dividend of
$.19 per share, paid on March 11, 1997 to shareowners of record on February 18,
1997.
The Company expects to continue the practice of paying regular cash
dividends.
NET EARNINGS PER SHARE AND CASH DIVIDENDS PAID PER SHARE
--------------------------------------------------------------------------------
Dollars Per Share
--------------------------------------------------------------------------------
COSTS AND EXPENSES
The percentage relationships of costs and expenses to sales for 1996, 1995 and
1994 were:
DISTRIBUTION OF SALES REVENUES - 1996
--------------------------------------------------------------------------------
--------------------------------------------------------------------------------
Research activities represent a significant part of the Company's business.
These expenditures relate to the development of new products, improvement of
existing products, technical support of products and compliance with
governmental regulations for the protection of the consumer. Worldwide costs of
research activities were as follows:
Research expense as a percent of sales for the Pharmaceutical segment was 15.2%,
15.3% and 14.9% in 1996, 1995 and 1994, respectively, while averaging 5.6%, 5.4%
and 4.8% in the other two segments.
24
RESEARCH EXPENSE
--------------------------------------------------------------------------------
Millions of Dollars
--------------------------------------------------------------------------------
Advertising expenses worldwide, which are comprised of television, radio
and print media, were $1.26 billion in 1996, $1.03 billion in 1995 and $800
million in 1994. Additionally, significant expenditures were incurred for
promotional activities such as couponing and performance allowances.
The Company believes that its operations comply in all material respects
with applicable environmental laws and regulations. The Company or its
subsidiaries are parties to a number of proceedings brought under the
Comprehensive Environmental Response, Compensation, and Liability Act, commonly
known as Superfund, and comparable state laws, in which the primary relief
sought is the cost of past and future remediation. While it is not feasible to
predict or determine the outcome of these proceedings, in the opinion of the
Company, such proceedings would not have a material adverse effect on the
results of operations, cash flows or financial position of the Company.
Statement of Position No. 96-1, "Environmental Remediation Liabilities,"
requires that environmental remediation liabilities be accrued when the criteria
of Financial Accounting Standards Board Statement of Financial Accounting
Standards No. 5, "Accounting for Contingencies," are met. The new standard,
which will be adopted in 1997, is not expected to have a material effect on the
Company's results of operations, cash flows or financial position.
Worldwide sales do not reflect any significant degree of seasonality;
however, spending has been heavier in the fourth quarter of each year than in
other quarters. This reflects increased spending decisions, principally for
advertising and research grants.
The worldwide effective income tax rate was 28.4% in 1996, 27.6% in 1995
and 25.2% in 1994. The increase in the 1996 worldwide effective tax rate was
primarily due to the increase in income subject to tax in the United States. See
page 34 for additional information.
A summary of operations and related statistical data for the years
1986-1996 can be found on page 42.
LIQUIDITY AND CAPITAL RESOURCES
Cash generated from operations and selected borrowings provide the major sources
of funds for the growth of the business, including working capital, additions to
property, plant and equipment and acquisitions. Cash and current marketable
securities totaled $2.14 billion at the end of 1996 as compared with $1.36
billion at the end of 1995.
Total unused credit available to the Company approximates $3.3 billion,
including $1.2 billion of credit commitments with various worldwide banks, $800
million of which expires on October 3, 1997 and $400 million on October 6, 2001.
During 1996, the Company issued $119 million equivalent of 5%
Euro-Deutsche Mark Notes due 2001. The proceeds were used for general corporate
purposes. The Company also redeemed its $200 million 8% Notes due 1998 and
Italian Lire 150 billion (U.S. $ equivalent of $95.4 million) 8.82% Notes due
2003 at par according to the call provisions of each debt issue. At December 29,
1996, the Company had $2.29 billion remaining on its shelf registration, which
was filed for $2.59 billion in October, 1994. A summary of borrowings can be
found on page 33.
Total borrowings at the end of 1996 and 1995 were $2.28 billion and $2.43
billion, respectively. In 1996 and 1995, net debt (debt net of cash and current
marketable securities) was 1.3% and 10.5% of net capital (shareowners' equity
and net debt), respectively. Total debt represented 17.4% and 21.2% of total
capital (shareowners' equity and total debt) in 1996 and 1995, respectively.
Shareowners' equity per share at the end of 1996 was $8.13 compared with the
stock split-adjusted $6.98 at year-end 1995, an increase of 16.5%.
Financial instruments are used to manage interest rate and foreign
exchange risks. The Company does not enter into derivative financial instruments
for trading or speculative purposes. The principal financial instruments used
are forward exchange contracts, and currency and interest rate swaps. Management
believes that the risk of incurring losses related to these instruments is
remote and that such losses, if any, would be immaterial. See page 37 for
additional information.
Additions to property, plant and equipment amounting to $1,373, $1,256 and
$937 million in 1996, 1995 and 1994, respectively, were made primarily to
increase the capacity of facilities for existing and new products. The Company
intends to continue this level of investment to support the business operations.
No material commitments for capital expenditures were outstanding at the end of
1996.
Statement of Financial Accounting Standard No. 121, "Accounting for the
Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of,"
requires that long-lived assets be reviewed for impairment whenever events or
changes in circumstances indicate that the carrying amount of the asset in
question may not be recoverable. The new standard, which was adopted in 1996,
did not have a material effect on the Company's results of operations, cash
flows or financial position.
During 1996, 1995 and 1994, certain businesses were acquired for $233,
$456 and $1,932 million, respectively. In 1995, the acquisition cost consisted
of $154 million in cash and 9.3 million shares, on a split-adjusted basis, of
the Company's common stock issued from treasury valued at $302 million. See page
38 for additional information.
The Company annually repurchases a sufficient amount of its common stock
in the open market to replace shares issued under various employee stock plans.
During 1996, the Company repurchased 8.7 million shares of its common stock at a
total cost of $412 million for use in the Company's employee benefit plans; 1995
and 1994 repurchases for this purpose totaled 9.2 million and 7.7 million
25
shares, on a split-adjusted basis, at a cost of $322 million and $185 million,
respectively.
Statement of Financial Accounting Standard No. 123, "Accounting for
Stock-Based Compensation," requires companies to measure employee stock
compensation plans based on the fair value method of accounting. However, the
Statement allows the alternative of continued use of Accounting Principles Board
(APB) Opinion No. 25, "Accounting for Stock Issued to Employees," with pro forma
disclosure of net income and earnings per share determined as if the fair value
based method had been applied in measuring compensation cost. The Company
adopted the new standard in 1996 and elected the continued use of APB Opinion
No. 25. Pro forma disclosure has not been provided, as the effect on 1996 net
earnings was immaterial.
CHANGING PRICES AND INFLATION
Johnson & Johnson is aware that its products are used in a setting where, for
more than a decade, policymakers, consumers and businesses have expressed
concern about the rising cost of health care. In response to these concerns,
Johnson & Johnson has a long standing policy of pricing products responsibly.
For the period 1980-1995, in the United States, the weighted average compound
growth rate of Johnson & Johnson's price increases for health care products
(prescription and over-the-counter drugs, hospital and professional products)
was below the U.S. Consumer Price Index (CPI) for the period. This was true
again in 1996.
Inflation rates, even though moderate in many parts of the world during
1996, continue to have an effect on worldwide economies and, consequently, on
the way companies operate. In the face of increasing costs, the Company strives
to maintain its profit margins through cost reduction programs, productivity
improvements and periodic price increases.
SEGMENTS OF BUSINESS
Financial information for the Company's three worldwide business segments is
summarized below. Refer to page 41 for additional information on segments of
business.
SALES BY SEGMENT OF BUSINESS
--------------------------------------------------------------------------------
Millions of Dollars
--------------------------------------------------------------------------------
OPERATING PROFIT BY SEGMENT OF BUSINESS
--------------------------------------------------------------------------------
Millions of Dollars
--------------------------------------------------------------------------------
CONSUMER
The Consumer segment's principal products are personal care and hygienic
products, including oral and baby care products, first aid products,
nonprescription drugs, sanitary protection products and adult skin and hair care
products. Major brands include ACT Fluoride Rinse; BAND-AID Brand Adhesive
Bandages; CAREFREE Panty Shields; JOHNSON'S CLEAN & CLEAR skin care products;
IMODIUM A-D, an antidiarrheal; JOHNSON'S Baby line of products; MONISTAT, a
remedy for vaginal yeast infections; MYLANTA gastrointestinal products and
PEPCID AC Acid Controller from the Johnson & Johnson o Merck Consumer
Pharmaceuticals Co.; NEUTROGENA skin and hair care products; NICOTROL smoking
cessation products; o.b. Tampons; PEDIACARE children's cold and allergy
medications; PENATEN and NATUSAN baby care products; PIZ BUIN and SUNDOWN sun
care products; REACH toothbrushes; RoC skin care products; SHOWER TO SHOWER
personal care products; STAYFREE and SURE & NATURAL sanitary protection
products; and the broad family of TYLENOL acetaminophen products. These products
are marketed principally to the general public and distributed both to
wholesalers and directly to independent and chain retail outlets.
Consumer segment sales in 1996 were $6.36 billion, an increase of 9.1%
over 1995. Sales by domestic companies accounted for 49.7% of the total segment,
while international companies accounted for 50.3%. The sales growth was led by
the strong performance of the OTC pharmaceutical business. PEPCID AC, a product
of the Johnson & Johnson o Merck Consumer Pharmaceuticals Co., and TYLENOL,
despite heavy competition, remain the dominant brands in their respective
categories. A strong performance by the adult skin and hair care franchise,
which includes the Neutrogena and RoC businesses, also contributed to the growth
in sales.
Consumer segment sales in 1995 were $5.83 billion, an increase of 11% over
1994. Sales by domestic companies accounted
26
for 49% of the total segment, while international companies accounted for 51%.
Growth was led by the addition of the Neutrogena line of high quality skin and
hair care products, which was acquired in the third quarter of 1994; the U.S.
launch of PEPCID AC Acid Controller, by Johnson & Johnson - Merck Consumer
Pharmaceuticals Co., and continued growth in international markets, most
notably Brazil. In addition to PEPCID AC, Children's MOTRIN, a nonprescription
children's fever and pain reliever that lasts up to eight hours, was introduced
as an over-the-counter product.
Consumer segment sales in 1994 were $5.25 billion, an increase of 8.9%
over 1993. Sales by domestic companies accounted for 51.3% of the total segment,
while international companies accounted for 48.7%. The worldwide Consumer
segment sales increase included the acquisitions of RoC S.A. in late 1993 and
Neutrogena at the end of the third quarter of 1994. Additionally, new products
such as TYLENOL Extended Relief, MYLANTA Soothing Lozenges and JOHNSON'S
HEALTHFLOW Infant Feeding System were introduced during the year.
Acquisitions and divestitures during 1996 and 1995 are described in more
detail on page 38.
PHARMACEUTICAL
The Pharmaceutical segment represents over 50% of operating profit for all
segments. The Pharmaceutical segment's principal worldwide franchises are in the
allergy, antibacterial, antifungal, biotech, central nervous system,
contraceptive, dermatology, gastrointestinal and immunobiology fields. These
products are distributed both directly and through wholesalers for use by health
care professionals and the general public.
Prescription drugs include DURAGESIC, a transdermal patch for chronic
pain; EPREX (sold in the U.S. as PROCRIT), a biotechnology derived version of
the human hormone erythropoietin, which stimulates red blood cell production;
ERGAMISOL, a colon cancer drug; FLOXIN, an antibacterial; HISMANAL, the
once-a-day less sedating antihistamine; IMODIUM, an antidiarrheal; LEUSTATIN,
for hairy cell leukemia; MOTILIUM, a gastrointestinal mobilizer; NIZORAL,
SPORANOX and TERAZOL, antifungals; ORTHOCLONE OKT-3, for reversing the rejection
of kidney, heart and liver transplants; ORTHO-NOVUM group of oral
contraceptives; PREPULSID (sold in the U.S. as PROPULSID), a gastrointestinal
prokinetic; RETIN-A, a dermatological cream for acne; RISPERDAL, an
antipsychotic drug; and ULTRAM, a new centrally acting prescription analgesic
for moderate to moderately severe pain.
Johnson & Johnson markets more than 90 prescription drugs around the
world, with 54% of the sales generated outside the United States. Twenty-six
drugs sold by the Company had 1996 sales in excess of $50 million, with 19 of
them in excess of $100 million.
Pharmaceutical segment sales in 1996 were $7.19 billion, an increase of
14.6% over 1995. Domestic sales advanced 24.4%, while international sales
advanced 7.2%. The worldwide growth was a result of the outstanding performances
of PROCRIT, RISPERDAL, SPORANOX, PROPULSID, ULTRAM, and DURAGESIC.
At year-end 1996, the Company received several FDA approvals for new
chemical entities as well as new indications for existing compounds. The new
chemical entities approved were LEVAQUIN, the first once-a-day anti-infective
which is proven effective against community-acquired pneumonia, acute maxillary
sinusitis and acute exacerbation of chronic bronchitis; and TOPAMAX, a new
antiepileptic drug proven to reduce the frequency of seizures.
Pharmaceutical segment sales in 1995 were $6.27 billion, an increase of
21.6% over 1994. Domestic sales advanced 25.9%, while international sales rose
18.6%. The worldwide sales growth reflects the outstanding performances of
RISPERDAL, PROPULSID, SPORANOX, DURAGESIC and PROCRIT. Additionally, ULTRAM,
launched in late March, was also an important contributor to sales growth.
Pharmaceutical segment sales in 1994 were $5.16 billion, an increase of
14.9% over 1993. Domestic sales advanced 20.7%, while international sales rose
11%. The worldwide sales increase was attributed to the outstanding growth of
RISPERDAL and the continued strong growth of PROPULSID. The sales increase was
also led by the strong growth of EPREX, PROCRIT, SPORANOX, DURAGESIC and FLOXIN.
Significant research activities continued in the Pharmaceutical segment,
increasing to $1,096 million in 1996, or $135 million over 1995. This represents
15.2% of 1996 Pharmaceutical sales and a compound growth rate of 15.3% for the
ten-year period since 1986.
Pharmaceutical research is led by two worldwide organizations, Janssen
Research Foundation, headquartered in Belgium and the R.W. Johnson
Pharmaceutical Research Institute, headquartered in the United States.
Additional research is conducted through a collaboration with the James Black
Foundation in London, England.
PROFESSIONAL
The Professional segment includes suture and mechanical wound closure products,
minimally invasive surgical instruments, diagnostic products, medical equipment
and devices, disposable contact lenses, surgical instruments, joint replacements
and products for wound management and infection prevention. These products are
used principally in the professional fields by physicians, dentists, nurses,
therapists, hospitals, diagnostic laboratories and clinics. Distribution to
these markets is done both directly and through surgical supply and other
dealers.
In 1996, Professional segment sales increased 19.8% over 1995, to $8.07
billion. The sales growth includes the full year impact of the merger with
Cordis Corporation in early 1996, and the continued growth of the interventional
cardiology business. Strong growth in the Asia-Pacific region also contributed
to the increase in the Professional segment, as did excellent performances by
LifeScan's blood glucose monitors, Vistakon's disposable contact lenses, Ethicon
Endo-Surgery's minimally invasive surgical instruments and Johnson & Johnson
Professional's orthopaedic business. Of the 1996 Professional segment sales,
domestic and international companies accounted for 54.3% and 45.7% of the total,
respectively.
In 1995, Professional segment sales increased 26.5% over 1994, to $6.74
billion. Strong sales growth was fueled by the rapid market acceptance of the
PALMAZ-SCHATZ Coronary Stent due to its efficacy in reducing restenosis, the
recurring blockage of coronary arteries following balloon angioplasty.
LifeScan's blood
27
glucose monitoring systems, Vistakon's disposable contact lenses, Ethicon
Endo-Surgery's minimally invasive surgical instruments and Ethicon sutures
continued to deliver solid growth. Johnson & Johnson Clinical Diagnostics, the
diagnostic business acquired from Eastman Kodak in November 1994, also
contributed to significant sales growth in the Professional segment. Of the 1995
Professional segment sales, domestic and international companies accounted for
54% and 46% of the total, respectively.
In 1994, Professional segment sales increased 10.4% over 1993, to $5.33
billion. Domestic sales posted a 6.4% increase, while international sales rose
15.8%. The worldwide Professional segment sales increase was attributed to the
continued growth of ACUVUE disposable contact lenses; ONE TOUCH II blood glucose
monitoring systems; the PALMAZ-SCHATZ Stent and various Ethicon Endo-Surgery
devices for less invasive surgery. Base businesses, such as Ethicon sutures,
also contributed significantly to the increase. Sales by domestic companies
accounted for 55.9% of the total segment, while international companies
accounted for 44.1%.
Acquisitions and divestitures during 1996 and 1995 are described in more
detail on page 38.
GEOGRAPHIC AREAS
The Company further categorizes its sales and operating profit by major
geographic area as presented for the years 1996 and 1995:
International sales and operating profit in 1996 were unfavorably impacted by
the translation of local currency operating results into U.S. dollars at lower
average exchange rates than in 1995. International sales and operating profit in
1995 were favorably impacted by the translation of local currency operating
results into U.S. dollars at higher average exchange rates than in 1994.
Operating profit reported above is before deduction of taxes on income and
certain income and expense items not allocated to segments, such as interest
expense, minority interests and general corporate income and expense.
See page 41 for additional information on geographic areas.
SALES BY GEOGRAPHIC AREA OF BUSINESS
--------------------------------------------------------------------------------
Millions of Dollars
--------------------------------------------------------------------------------
OPERATING PROFIT BY GEOGRAPHIC AREA OF BUSINESS
--------------------------------------------------------------------------------
Millions of Dollars
-------------------------------------------------------------------------------
DESCRIPTION OF BUSINESS
The company, employing 89,300 employees worldwide, is engaged in the manufacture
and sale of a broad range of products in the health care field in virtually all
countries of the world. The Company's primary interest, both historically and
currently, has been in products related to health and well-being.
The Company is organized on the principles of decentralized management.
The Executive Committee of Johnson & Johnson is the principal management group
responsible for the operations of the Company. In addition, three Executive
Committee members are Chairmen of Group Operating Committees, which are
comprised of managers who represent key operations within the group, as well as
management expertise in other specialized functions. These Committees oversee
and coordinate the activities of domestic and international companies related to
each of the Consumer, Pharmaceutical and Professional businesses. Operating
management of each company is headed by a Chairman, President, General Manager
or Managing Director who reports directly to or through a Company Group
Chairman.
In line with this policy of decentralization, each international
subsidiary is, with some exceptions, managed by citizens of the country where it
is located. The Company's international business is conducted by subsidiaries
manufacturing in 39 countries outside the United States and selling in over 175
countries throughout the world.
In all its product lines, the Company competes with companies both large
and small, located in the U.S. and abroad. Competition is strong in all lines
without regard to the number and size of the competing companies involved.
Competition in research, involving the development of new products and processes
and the improvement of existing products and processes, is particularly
significant and results from time to time in product and process obsolescence.
The development of new and improved products is important to the Company's
success in all areas of its business. This competitive environment requires
substantial investments in continuing research and in multiple sales forces. In
addition, the winning and retention of customer acceptance of the Company's
consumer products involves heavy expenditures for advertising, promotion and
selling.
28
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS Johnson & Johnson and Subsidiaries
1 SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
PRINCIPLES OF CONSOLIDATION
The consolidated financial statements include the accounts of Johnson & Johnson
and subsidiaries. Intercompany accounts and transactions are eliminated.
CASH EQUIVALENTS
The Company considers securities with maturities of three months or less, when
purchased, to be cash equivalents.
REVENUE RECOGNITION
The Company recognizes revenue from product sales when the goods are shipped
to the customer.
INVENTORIES
Inventories are stated at the lower of cost (determined principally by the
first-in, first-out method) or market.
DEPRECIATION OF PROPERTY
The Company utilizes the straight-line method of depreciation for financial
statement purposes for all additions to property, plant and equipment placed in
service after January 1, 1989. Property, plant and equipment placed in service
prior to January 1, 1989 is generally depreciated using an accelerated method.
INTANGIBLE ASSETS
The excess of the cost over the fair value of net assets of purchased businesses
is recorded as goodwill and is amortized on a straight-line basis over periods
of 40 years or less. The cost of other acquired intangibles is amortized on a
straight-line basis over their estimated useful lives. The Company continually
evaluates the carrying value of goodwill and other intangible assets. Any
impairments would be recognized when the expected future operating cash flows
derived from such intangible assets is less than their carrying value.
LONG-LIVED ASSETS
Statement of Financial Accounting Standard No. 121, "Accounting for the
Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of,"
requires that long-lived assets be reviewed for impairment whenever events or
changes in circumstances indicate that the carrying amount of the asset in
question may not be recoverable. The new standard, which was adopted in 1996,
did not have a material effect on the Company's results of operations, cash
flows or financial position.
FINANCIAL INSTRUMENTS
Gains and losses on foreign currency hedges of existing assets or liabilities,
or hedges of firm commitments are deferred and are recognized in income as part
of the related transaction.
ADVERTISING
Costs associated with advertising are expensed in the year incurred.
Advertising expenses worldwide, which are comprised of television, radio and
print media, were $1.26 billion, $1.03 billion and $.8 billion in 1996, 1995 and
1994, respectively.
INCOME TAXES
The Company intends to continue to reinvest its undistributed international
earnings to expand its international operations; therefore, no tax has been
provided to cover the repatriation of such undistributed earnings. At December
29, 1996 and December 31, 1995 the cumulative amount of undistributed
international earnings was approximately $5.5 billion and $4.7 billion,
respectively.
NET EARNINGS PER SHARE
Net earnings per share were calculated using the average number of shares
outstanding during each year. Shares issuable under stock option and
compensation plans would not materially reduce net earnings per share. All share
and per share amounts have been restated to retroactively reflect the current
and prior year stock splits.
RISKS AND UNCERTAINTIES
The preparation of consolidated financial statements in conformity with
generally accepted accounting principles requires management to make estimates
and assumptions that affect the amounts reported. Actual results are not
expected to differ from those estimates.
ANNUAL CLOSING DATE
The Company follows the concept of a fiscal year which ends on the Sunday
nearest to the end of the month of December. Normally each fiscal year consists
of 52 weeks, but every five or six years, as will be the case in 1998, the
fiscal year consists of 53 weeks.
RECLASSIFICATION
Certain prior year amounts have been reclassified to conform with current year
presentation.
2 INVENTORIES
At the end of 1996 and 1995, inventories were comprised of:
3 PROPERTY, PLANT AND EQUIPMENT
At the end of 1996 and 1995, property, plant and equipment at cost and
accumulated depreciation consisted of:
32
The Company capitalizes interest expense as part of the cost of construction of
facilities and equipment. Interest expense capitalized in 1996, 1995 and 1994
was $55, $70 and $44 million, respectively.
Upon retirement or other disposal of fixed assets, the cost and related
amount of accumulated depreciation or amortization are eliminated from the asset
and reserve accounts, respectively. The difference, if any, between the net
asset value and the proceeds is adjusted to income.
4 INTANGIBLE ASSETS
At the end of 1996 and 1995, intangible assets, consisting primarily of patents,
trademarks and goodwill, comprised:
--------------------------------------------------
5 BORROWINGS
The components of long-term debt are as follows:
(1) These debt issues include the effect of foreign currency movements in the
principal amounts shown. Such debt was converted to fixed or floating rate U.S.
dollar liabilities via interest rate and currency swaps. Unrealized currency
gains (losses) on currency swaps are not included in the basis of the related
debt transactions which such swaps hedge and are classified in the balance sheet
as other assets (liabilities). Also, see Note 16.
(2) Weighted average effective rate.
(3) Represents 5% Deutsche Mark notes due 2001 issued by a Japanese subsidiary
and converted to a 1.98% fixed rate yen note via an interest rate and currency
swap.
The Company has access to substantial sources of funds at numerous banks
worldwide. Total unused credit available to the Company approximates $3.3
billion, including $1.2 billion of credit commitments with various worldwide
banks, $800 million of which expire on October 3, 1997 and $400 million on
October 6, 2001. Borrowings under the credit line agreements will bear interest
based on either bids provided by the banks, the prime rate or London Interbank
Offered Rates (LIBOR), plus applicable margins. Commitment fees under the
agreements are not material.
In 1994, the Company filed a shelf registration with the Securities and
Exchange Commission, and in combination with $585 million remaining from a prior
shelf registration, initiated a third series of its Medium Term Note Program
(MTN) for the issuance of up to $2.59 billion of unsecured debt securities and
warrants to purchase debt securities. No MTN's were issued during 1996 or 1995.
In 1996, the Company issued $119 million equivalent of 5% Euro-Deutsche Mark
notes due 2001. The proceeds were used for general corporate purposes. The
Company also redeemed its $200 million 8% Notes due 1998 and Italian Lire 150
billion (U.S. equivalent $95.4 million) 8.82% Notes due 2003 at par according to
the call provisions of each debt issue. At December 29, 1996, the Company had
$2.29 billion remaining on its shelf registration.
Short-term borrowings amounted to $872 million at the end of 1996. These
borrowings are composed of $186 million of European currency notes, $200 million
of Eurodollar notes, $112 million of Swiss Franc notes and $374 million of local
borrowings principally by international subsidiaries.
Interest rates on the Industrial Revenue Bonds vary from 5% to 6%, while
rates on other long-term obligations vary from 2% to 20% according to local
conditions.
Aggregate maturities of long-term obligations for each of the next five years
commencing in 1997 are:
6 INCOME TAXES
The provision for taxes on income consists of:
Deferred income taxes are recognized for tax consequences of "temporary
differences" by applying enacted statutory tax rates, applicable to future
years, to differences between the financial reporting and the tax basis of
existing assets and liabilities.
33
Temporary differences and carryforwards for 1996 are as follows:
A comparison of income tax expense at the federal statutory rate of 35% in 1996,
1995 and 1994, to the Company's effective tax rate is as follows:
The increase in the 1996 worldwide effective tax rate was primarily due to the
increase in income subject to tax in the United States.
During 1996, the Company had subsidiaries operating in Puerto Rico under a
grant for tax relief expiring December 31, 2007. The Omnibus Budget
Reconciliation Act of 1993 includes a change in the tax code which will reduce
the benefit the Company receives from its operations in Puerto Rico by 60%
gradually over a five-year period. The Small Business Job Protection Act of 1996
repealed the Puerto Rico tax credit; however, the Company, as an existing credit
claimant, may claim the credit for an additional 10 year period. In addition,
the Company has subsidiaries manufacturing in Ireland under an incentive tax
rate expiring on December 31, 2010.
--------------------------------------------------------------------------------
7 INTERNATIONAL CURRENCY TRANSLATION
For translation of its international currencies, the Company has
determined that the local currencies of its international subsidiaries are the
functional currencies except those in highly inflationary economies, which are
defined as those which have had compound cumulative rates of inflation of 100%
or more during the past three years.
In consolidating international subsidiaries, balance sheet currency effects
are recorded as a separate component of shareowners' equity. This equity account
includes the results of translating all balance sheet assets and liabilities at
current exchange rates, except for those located in highly inflationary
economies, principally Latin America, which are reflected in operating results.
An analysis of the changes during 1996 and 1995 in the separate component of
shareowners' equity for cumulative currency translation adjustments follows:
Net currency transaction and translation gains and losses included in other
expense were after-tax gains of $2 million in 1996, and losses of $14 and $4
million in 1995 and 1994, respectively.
--------------------------------------------------------------------------------
8 INTERNATIONAL SUBSIDIARIES
The following amounts are included in the consolidated financial statements for
international subsidiaries:
International sales to customers were $10,721, $9,652, and $7,922 million for
1996, 1995 and 1994, respectively.
9 RENTAL EXPENSE AND LEASE COMMITMENTS
Rentals of space, vehicles, manufacturing equipment and office and data
processing equipment under operating leases amounted to approximately $237
million in 1996, $227 million in 1995 and $207 million in 1994.
The approximate minimum rental payments required under operating leases that
have initial or remaining noncancellable lease terms in excess of one year at
December 29, 1996 are:
Commitments under capital leases are not significant.
--------------------------------------------------------------------------------
10 COMMON STOCK, STOCK OPTION PLANS AND STOCK COMPENSATION AGREEMENTS
At December 29, 1996 the Company had five stock-based compensation plans. Under
the 1995 Employee Stock Option Plan, the Company may grant options to its
employees for up to 56 million shares of common stock. The shares outstanding
are for contracts under the Company's 1986, 1991 and 1995 Employee Stock Option
Plans, and the Mitek and Cordis Employee Stock Option Plans.
34
Stock options expire in ten years from the date they are granted and vest
over service periods that range from two to six years. Shares available for
future grants amounted to 32.9 million, 40.1 million and 8.3 million in 1996,
1995 and 1994, respectively.
A summary of the status of the Company's stock option plans as of December
29, 1996 and December 31, 1995, and changes during the years ending on those
dates, is presented below:
* Adjusted to reflect the 1996 two-for-one stock split
Statement of Financial Accounting Standard No. 123, "Accounting for
Stock-Based Compensation," requires companies to measure employee stock
compensation plans based on the fair value method of accounting. However, the
Statement allows the alternative of continued use of Accounting Principles Board
(APB) Opinion No. 25, "Accounting for Stock Issued to Employees," with pro forma
disclosure of net income and earnings per share determined as if the fair value
based method had been applied in measuring compensation cost. The Company
adopted the new standard in 1996 and elected the continued use of APB Opinion
No. 25. Pro forma disclosure has not been provided, as the effect on 1996 net
earnings was immaterial.
The following table summarizes stock options outstanding and exercisable at
December 29, 1996.
(a) Average contractual life remaining in years
11 CERTIFICATES OF EXTRA COMPENSATION
The Company has a deferred compensation program for senior management and other
key personnel. The value of units awarded under the program is related to the
net asset value of the Company and historical earning power of its common stock.
Amounts earned under the program are payable only after employment with the
Company has ended.
12 SEGMENTS OF BUSINESS AND GEOGRAPHIC AREAS
See page 41 for information on segments of business and geographic areas.
13 RETIREMENT AND PENSION PLANS
The Company sponsors various retirement and pension plans, including defined
benefit, defined contribution and termination indemnity plans, which cover most
employees worldwide.
Plan benefits are primarily based on the employee's compensation during the
last three to five years before retirement and the number of years of service.
The Company's objective in funding its domestic plans is to accumulate funds
sufficient to provide for all accrued benefits. International subsidiaries have
plans under which funds are deposited with trustees, annuities are purchased
under group contracts, or reserves are provided.
In certain countries other than the United States, the funding of pension
plans is not a common practice as funding provides no economic benefit.
Consequently, the Company has several pension plans which are not funded.
Net pension expense for the Company's defined benefit plans for 1996, 1995
and 1994 included the following components:
The net periodic pension cost attributable to domestic plans and included above
was $84 million in 1996, $43 million in 1995 and $49 million in 1994.
The following tables provide the domestic assumptions and the range of
international assumptions, which are based on the economic environment of each
applicable country, used to develop net periodic pension cost and the actuarial
present value of projected benefit obligations:
35
The following table sets forth the actuarial present value of benefit
obligations and funded status at year-end 1996 and 1995 for the Company's
defined benefit plans:
14 SAVINGS PLAN
The Company has voluntary 401(k) savings plans designed to enhance the existing
retirement programs covering eligible employees. The Company matches a
percentage of each employee's contributions consistent with the provisions of
the plan for which he/she is eligible.
In the U.S. salaried plan, one-third of the Company match is paid in Company
stock under an employee stock ownership plan (ESOP). In 1990, to establish the
ESOP, the Company loaned $100 million to the ESOP Trust to purchase shares of
Company stock on the open market. In exchange, the Company received a note, the
balance of which is recorded as a reduction of shareowners' equity.
Total Company contributions to the plans were $50 million in 1996, $45
million in 1995 and $41 million in 1994.
15 OTHER POSTRETIREMENT BENEFITS
The Company provides postretirement benefits, primarily health care, to all
domestic retired employees and their dependents. Most international employees
are covered by government-sponsored programs and the cost to the Company is not
significant. The Company does not fund retiree health care benefits in advance
and has the right to modify these plans in the future.
The net periodic postretirement benefit costs for retirees included the
following components:
The plans' status as of year-end 1996 and 1995 was as follows:
36
The postretirement benefit obligation was determined by application of the terms
of the various plans, together with relevant actuarial assumptions. Health care
cost trends are projected at annual rates grading from 11% for employees under
age 65 and 8% for employees over age 65 down to 5% for both groups by the year
2008 and beyond. The effect of a 1% annual increase in these assumed cost trend
rates would increase the accumulated postretirement benefit obligation at
year-end by $66 million and the service and interest cost components of the net
periodic postretirement benefit cost for 1996 by a total of $9 million.
Assumptions used to develop net periodic postretirement benefit cost and the
actuarial present value of projected postretirement benefit obligations were as
follows:
The Company also provides postemployment benefits to qualified former or
inactive employees. The Company does not fund these benefits and has the right
to modify these plans in the future.
16 FINANCIAL INSTRUMENTS
DERIVATIVE FINANCIAL INSTRUMENT RISK
The Company uses derivative financial instruments to reduce exposures to market
risks resulting from fluctuations in interest rates and foreign exchange. The
Company does not enter into financial instruments for trading or speculative
purposes.
The Company has a policy of only entering into contracts with parties that
have at least an "A" (or equivalent) credit rating. The counterparties to these
contracts are major financial institutions and the Company does not have
significant exposure to any one counterparty. Management believes that risk of
loss is remote and in any event would be immaterial.
INTEREST RATE RISK MANAGEMENT
The Company uses interest rate and currency swaps to manage interest rate risk
related to borrowings. Interest rate and currency swap agreements which hedge
third party debt issues mature with these borrowings and are described in Note
5.
Forward rate agreements (FRA) are used by the Company to fix the rates
received on short-term floating-rate investments and mature within 1 year. There
were no FRA's outstanding at the end of 1996.
The following table illustrates the notional amounts outstanding, maturity
dates, and the weighted average receive and pay rates of interest rate hedge
agreements by type. (Notional amounts provide an indication of the extent of the
Company's involvement in such agreements but do not represent its exposure to
market risk.)
(1) Variable rates are primarily indexed to the Federal Reserve H.15 30 day
commercial paper rate.
Interest expense under these agreements, and the respective debt instruments
that they hedge, are recorded at the net effective interest rate of the hedged
transactions.
FOREIGN EXCHANGE RISK MANAGEMENT
The Company enters into forward exchange contracts to hedge product costs and
revenues that are denominated in foreign currencies and currency swaps to hedge
foreign currency denominated debt. These hedging instruments are classified
consistent with the item being hedged.
The Company enters into various types of foreign exchange contracts maturing
within five years. The Company has forward exchange contracts outstanding at
year-end in various currencies principally in U.S. Dollars, Japanese Yen and
Belgian Francs. In addition, the Company has currency swaps outstanding
principally in U.S. Dollars, French Francs and Belgian Francs. Deferred
unrealized gains and losses, based on dealer-quoted prices, from hedging firm
commitments are presented in the following table:
FAIR VALUE OF FINANCIAL INSTRUMENTS
The carrying amount of cash and cash equivalents approximates fair value due to
the short-term maturities of these instruments. The fair value of current and
non-current marketable securities, long-term debt and foreign interest rate and
currency swap agreements (used to hedge third party debt issues) were estimated
based on quotes obtained from brokers for those or similar instruments. The fair
value of foreign interest rate and currency contracts (used for hedging
purposes) and long-term investments were estimated based on quoted market prices
at year-end.
The estimated fair value of the Company's financial instruments are as
follows:
(1) Primarily included in other assets on the balance sheet.
The carrying amounts in the table are included in the statement of financial
position under the indicated captions.
CONCENTRATION OF CREDIT RISK
The Company invests its excess cash in both deposits with major banks throughout
the world and other high quality short-term liquid money market instruments
(commercial paper, government and government agency notes and bills, etc.). The
Company has a policy of making investments only with commercial institutions
that have at least an "A" (or equivalent) credit rating. These investments
generally mature within six months and the Company has not incurred any related
losses.
The Company sells a broad range of products in the health care field in
most countries of the world. Concentrations of credit risk with respect to trade
receivables are limited due to the large number of customers comprising the
Company's customer base. Ongoing credit evaluations of customers' financial
condition are performed and, generally, no collateral is required. The Company
maintains reserves for potential credit losses and such losses, in the
aggregate, have not exceeded management's expectations.
--------------------------------------------------------------------------------
17 MERGER, ACQUISITIONS AND DIVESTITURES
On February 23, 1996 Johnson & Johnson and Cordis Corporation completed the
merger between the two companies. The merger has been accounted for as a pooling
of interests; however, prior period financial statements have not been restated
as the effect of reflecting data relating to this merger would not materially
effect previously issued financial statements.
Johnson & Johnson issued 2.2584 shares of stock, on a split-adjusted
basis, for each share of Cordis stock. The exchange ratio resulted from dividing
$109 (exchange value of Cordis shares) by the average of the closing prices for
Johnson & Johnson shares for the 10 days prior to the merger. At the time of the
merger, Cordis had approximately 17.6 million shares outstanding on a fully
diluted basis, resulting in a total value, net of cash, of approximately $1.8
billion.
Cordis is a leader in angiography and angioplasty (balloon catheters). The
combination of Cordis and Johnson & Johnson's interventional cardiology business
was an important strategic step for both companies to meet the challenge of
providing for customer needs in the fast changing health care industry.
During 1996 certain businesses were acquired for $233 million. The 1996
acquisitions included Indigo Medical, Inc., a pioneer in the use of advanced,
low cost diode lasers for interstitial thermotherapy and the exercise of our
option to purchase the trademarks of Lactaid, Inc., producer of the natural
dairy digestive supplement LACTAID.
The excess of purchase price over the estimated fair market value of 1996
acquisitions amounted to $205 million. This amount has been allocated to
identifiable intangibles and goodwill. Pro forma information is not provided for
1996 as the impact of the acquisitions does not have a material effect on the
Company's results of operations, cash flows or financial position.
In 1995 certain businesses were acquired for $456 million consisting of
$154 million in cash and 9,312,000 shares, on a split-adjusted basis, of the
Company's stock issued from treasury valued at $302 million. These acquisitions
were accounted for by the purchase method and accordingly the results of
operations of the acquired businesses have been included in the accompanying
consolidated financial statements from their respective dates of acquisition.
The 1995 acquisitions included: Mitek Surgical Products, Inc., a
manufacturer and marketer of suture anchor products for soft tissue
reattachment; Menlo Care, Inc., a manufacturer and marketer of vascular access
products to hospital and home health care professionals; Joint Medical Products
Inc., a developer and marketer of artificial hips (S-Rom TM) and knee joints;
Gyno Pharma, Inc., the exclusive licensor and marketer of the PARAGARD T380A
(intrauterine device) in the United States and UltraCision, Inc., the developer
and manufacturer of ultrasonic surgical instruments (Harmonic Scalpel TM).
38
The excess of purchase price over the estimated fair market value of 1995
acquisitions amounted to $435 million. This amount has been allocated to
identifiable intangibles and goodwill. Pro forma information is not provided for
1995 as the impact of the acquisitions does not have a material effect on the
Company's results of operations, cash flows or financial position.
Divestitures in 1996 did not have a material effect on the Company's
results of operations, cash flows or financial position.
In 1995, the Company completed the sales of Johnson & Johnson Advanced
Materials Company and Chicopee B.V., Netherlands, worldwide developers and
marketers of non-woven materials used in a broad range of health care, consumer
and industrial applications. In addition, the Company sold the IOLAB ophthalmic
surgical business to Chiron Vision, a division of Chiron Corporation.
The 1995 divestitures resulted in an after-tax capital gain of $103
million. The after-tax gains on the 1995 divestitures were reinvested in certain
base businesses.
--------------------------------------------------------------------------------
18 PENDING LEGAL PROCEEDINGS
The Company is involved in numerous product liability cases in the United
States, many of which concern adverse reactions to drugs and medical devices.
The damages claimed are substantial, and while the Company is confident of the
adequacy of the warnings which accompany such products, it is not feasible to
predict the ultimate outcome of litigation. However, the Company believes that
if any liability results from such cases for injuries occurring on or before
December 31, 1985, it will be substantially covered by insurance.
Due to the general unavailability of traditional liability insurance,
including product liability insurance, the Company is substantially uninsured
for injuries occurring on or after January 1, 1986. The Company has a
self-insurance program which provides reserves for such injuries based on claims
experience.
Additionally, the Company, along with numerous other pharmaceutical
manufacturers and distributors, is a defendant in a large number of individual
and class actions brought by retail pharmacies in state and federal courts under
the antitrust laws. These cases assert price discrimination and price-fixing
violations resulting from an alleged industry-wide agreement to deny retail
pharmacists price discounts on sales of brand name prescription drugs. The
Company believes the claims against the Company in these actions are without
merit and is defending them vigorously.
The Company is also involved in a number of patent, trademark and other
lawsuits incidental to its business.
The Company believes that the above proceedings in the aggregate would not
have a material adverse effect on its results of operations, cash flows or
financial position.
--------------------------------------------------------------------------------
19 SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)
Selected unaudited quarterly financial data for the years 1996 and 1995 is
summarized below:
*Adjusted to reflect the 1996 two-for-one stock split
39
REPORT OF MANAGEMENT
--------------------------------------------------------------------------------
The management of Johnson & Johnson is responsible for the integrity and
objectivity of the accompanying financial statements and related information.
The statements have been prepared in conformity with generally accepted
accounting principles, and include amounts that are based on our best judgements
with due consideration given to materiality.
Management maintains a system of internal accounting controls monitored by
a corporate staff of professionally trained internal auditors who travel
worldwide. This system is designed to provide reasonable assurance, at
reasonable cost, that assets are safeguarded and that transactions and events
are recorded properly. While the Company is organized on the principles of
decentralized management, appropriate control measures are also evidenced by
well-defined organizational responsibilities, management selection, development
and evaluation processes, communicative techniques, financial planning and
reporting systems and formalized procedures.
It has always been the policy and practice of the Company to conduct its
affairs ethically and in a socially responsible manner. This responsibility is
characterized and reflected in the Company's Credo and Policy on Business
Conduct which are distributed throughout the Company. Management maintains a
systematic program to ensure compliance with these policies.
Coopers & Lybrand L.L.P., independent auditors, is engaged to audit our
financial statements. Coopers & Lybrand L.L.P. obtains and maintains an
understanding of our internal controls and conducts such tests and other
auditing procedures considered necessary in the circumstances to express their
opinion in the report that follows.
The Audit Committee of the Board of Directors, composed solely of outside
directors, meets periodically with the independent auditors, management and
internal auditors to review their work and confirm that they are properly
discharging their responsibilities. In addition, the independent auditors, the
General Counsel and the Vice President, Internal Audit are free to meet with the
Audit Committee without the presence of management to discuss the results of
their work and observations on the adequacy of internal financial controls, the
quality of financial reporting and other relevant matters.
/s/ Ralph S. Larsen /s/ Clark H. Johnson
Ralph S. Larsen Clark H. Johnson
Chairman, Board of Directors Vice President, Finance
and Chief Executive Officer and Chief Financial Officer
INDEPENDENT AUDITOR'S REPORT
--------------------------------------------------------------------------------
To the Shareowners and Board of Directors of Johnson & Johnson:
We have audited the accompanying consolidated balance sheet of Johnson & Johnson
and subsidiaries as of December 29, 1996 and December 31, 1995, and the related
consolidated statement of earnings, consolidated statement of common stock,
retained earnings and treasury stock, and consolidated statement of cash flows
for each of the three years in the period ended December 29, 1996. These
financial statements are the responsibility of the Company's management. Our
responsibility is to express an opinion on these financial statements based on
our audits.
We conducted our audits in accordance with generally accepted auditing
standards. Those standards require that we plan and perform the audit to obtain
reasonable assurance about whether the financial statements are free of material
misstatement. An audit includes examining, on a test basis, evidence supporting
the amounts and disclosures in the financial statements. An audit also includes
assessing the accounting principles used and the significant estimates made by
management, as well as evaluating the overall financial statement presentation.
We believe that our audits provide a reasonable basis for our opinion.
In our opinion, the financial statements referred to above present fairly,
in all material respects, the consolidated financial position of Johnson &
Johnson and subsidiaries as of December 29,1996 and December 31, 1995, and the
results of its operations and its cash flows for each of the three years in the
period ended December 29, 1996, in conformity with generally accepted accounting
principles.
/s/ Coopers & Lybrand L.L.P.
New York, New York
January 20, 1997
40
SEGMENTS OF BUSINESS(1) Johnson & Johnson and Subsidiaries
GEOGRAPHIC AREAS
(1) See Management's Discussion and Analysis, pages 26 to 28, for a description
of the segments in which the Company does business.
(2) Export sales and intersegment sales are not significant. No single customer
represents 10% or more of total sales.
(3) Expenses not allocated to segments include interest expense, minority
interests and general corporate income and expense.
41
Johnson & Johnson and Subsidiaries
SUMMARY OF OPERATIONS AND STATISTICAL DATA 1986-1996
*Adjusted to reflect the 1996 two-for-one stock split
(1) After the cumulative effect of accounting changes of $595 million.
- 1992 earnings percent of sales to customers before
accounting changes is 11.8%.
- 1992 earnings percent return on average shareowners'
equity before accounting changes is 28.5%.
- 1993 net earnings per share percent increase over prior
year before accounting change is 11.4%;
1992 is 12.3%.
(2) After Latin America non-recurring charges of $125 million.
- 1990 net earnings percent of sales to customers before
non-recurring charges is 11.3%.
- 1990 percent return on average shareowners' equity
before non-recurring charges is 27.6%.
- 1991 net earnings per share percent increase over prior
year before non-recurring charges is 15.3%;
1990 is 17.3%.
(3) After one-time charges of $380 million.
- 1986 earnings percent of sales before one-time charges
is 10.1%.
- 1986 percent return on average shareowners' equity
before one-time charges is 21.6%.
- 1987 net earnings per share percent increase over prior
year before one-time charges is 22.2%; 1986 is 17.9%.
(4) Includes Latin America non-recurring charge of $36 million for
the liquidation of Argentine debt.
(5) Net of interest and other income.
(6) Also included in cost of materials and services category.
(7) Includes taxes on income, payroll, property and other business taxes.
42
THREE YEARS IN BRIEF-WORLDWIDE
*Adjusted to reflect the 1996 two-for-one stock split
DESCRIPTION OF THE COMPANY
Johnson & Johnson, with $21.6 billion in sales, is the world's largest and most
comprehensive manufacturer of health care products serving the consumer,
pharmaceutical and professional markets. Johnson & Johnson has 89,300 employees
and more than 170 operating companies in 50 countries around the world, selling
products in more than 175 countries.
ON THE COVER
Dr. Zhu Hong-Sheng typifies surgeons throughout China, who are able to better
care for their patients with high quality ETHICON Silk Sutures, now that the
Company has begun local manufacturing in Shanghai.
CONTENTS
1 Letter to Shareowners
4 Editorial Section
23 Management's Discussion and Analysis of Results
29 Consolidated Financial Statements
32 Notes to Consolidated Financial Statements
40 Report of Management
40 Independent Auditor's Report
41 Segments of Business and Geographic Areas
42 Summary of Operations and Statistical Data 1986-1996
43 Principal Global Affiliates
46 Worldwide Family of Companies
50 Board of Directors and Committees of the Board
51 Corporate Officers, Company Group Chairmen, Corporate and Shareowner
Information